Follow the progress of Hemolens Diagnostics
This website contains information intended only for persons professionally dealing with medical devices (e.g. for persons performing medical professions, for persons dealing with the distribution of medical devices). Please confirm that you are a medical device professional to proceed.
Follow the progress of Hemolens Diagnostics
March 7, 2023
The Start-Up-Med competition is a prestigious initiative organized by PTWP Group (Polish Association for Entrepreneurship Support), publisher of, among others, the rynekzdrowia.pl portal and the Rynek Zdrowia magazine. The initiative aims to honor the most innovative and prospective solutions in the medical industry. This year, one of the winners was Hemolens Diagnostics, whose technology attracted a lot of attention from the jury and industry experts.
Hemolens Diagnostics operates in the medical diagnostics sector and is focused on developing cutting-edge technology to provide a fast and accurate diagnosis of ischemic heart disease. Hemolens Diagnostics’ innovative approach to diagnostics aims to improve the quality of healthcare and accelerate the diagnostics of coronary heart disease.
The technology developed by Hemolens Diagnostics is based on the use of computational fluid dynamics, allowing for personalized diagnostics by calculating the FFR-CT (fractional flow reserve) index in the coronary arteries. Compared to traditional diagnostic methods, the Hemolens Diagnostics technology can enable faster diagnosis of coronary artery disease, which will impact the effectiveness of treatment.
As a result of a vote by the Start-Up-Med jury, Hemolens Diagnostics was honored out of 70 submitted companies for its innovative technology and potential in the medical industry. Hemolens Diagnostics’ success is a prestigious award and an opportunity to develop the company and launch the technology on the medical market.
Recognition at Start-Up-Med is confirmation that it is worthwhile to be involved in the development of innovative diagnostic solutions and to strive to improve the diagnosis of heart disease. Thanks to the PWTR Group’s initiatives, Hemolens Diagnostics has the opportunity to present its proprietary idea to a wide audience at the Health Challenges Congress in Katowice on 9 March 2023.
June 23, 2023
Warsaw, 22 June 2023. – Wrocław-based Hemolens Diagnostics has been awarded this year’s “Polonica Progressio” award by the Minister...
June 21, 2023
Physical activity plays a key role in the prevention of cardiovascular disease and other cardiovascular disorders. Research shows that...
May 26, 2023
Wrocław, April 21, 2023. – Wrocław-based Hemolens Diagnostics has been recognized in this year’s Polish Product of the Future...
March 20, 2023
Huawei Startup Academy is an initiative that was created for young, promising startups, offering them not only the opportunity...
March 1, 2023
Rebranding is a process aimed at changing one or more elements of a brand’s image communication. This includes changes...
February 24, 2023
The research project ‘HEMOFLOW cloud platform for non-invasive hemodynamic diagnostics’, No. POIR.01.01.01-00-0393/19, aims to assess the diagnostic value of...
January 11, 2023
What is FFR Measuring fractional flow reserve (FFR) is currently the ‘gold standard’ in the diagnostic assessment of coronary...
November 21, 2022
On 10 November at the ISPOR 2022 Europe conference, independent research company Panaxea presented the results of a study...
Cardiolens FFR-CT Pro is a coronary physiologic simulation software for the clinical quantitative and qualitative analysis of previously acquired Coronary Computed Tomography Angiography (CCTA) and optionally with Continuous Non-invasive Blood Pressure (CNBP) data for assessment of patients with suspected Chronic Coronary Syndromes (CCS). It provides hemodynamic diagnostic factor FFR-CT (Fractional Flow Reserve with Computed Tomography), a mathematically derived quantity, computed from simulated pressure, velocity and blood flow information obtained from a 3D computer model generated from static coronary CT images and optionally from CNBP measurement. The factor FFR-CT at the output of Cardiolens FFR-CT Pro device is intended to support the functional evaluation of coronary artery disease. The Cardiolens FFR-CT Pro outputs are provided to support qualified clinicians to aid in the evaluation and assessment of coronary arteries. The results of Cardiolens FFR-CT Pro are intended to be used by qualified clinicians in conjunction with the patient’s clinical history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgment.